We are a multi-disciplinary clinic using cutting edge biological research that is committed to revolutionising your health.

About FOY’s

Foy’s Clinic, a luxury modern centre for preventative medicine and regenerative stem cell therapy clinic. Our high-class professionals and experts in different fields have been advancing our stem cell therapy internationally to offer you the cream of the crop.

In collaboration with research & development institutions, our founders initiated and conducted the unique large-scale research and clinical trials in all the existing disease models. The results were surprising and very promising, and the efforts of the team were crowned by many discoveries

Autism

Autism

Autism spectrum disorder affects an individual’s ability to communicate and form relationships with other people from early childhood. Autism also affects an individual’s ability to use language as well as abstract concepts.

Diabetes

Diabetes

Diabetes is a medical condition that occurs when the body is unable to regulate the sugar concentration in the blood; the concentration is regulated by insulin which is triggered by b-cells when there is an increase in blood glucose.

MS

MS

Multiple Sclerosis is a chloric and unpredictable neurological disorder of the central nervous system which consists of the spinal cord, optical nerves, and brain. The disorder causes dysfunctions of the neurons as a result of myelin destruction.

Cancer

Cancer

Cancer is a group of diseases caused by uncontrollable cell growth which causes the formation of lumps of tissues called tumor; these tumors grow and start to interfere with the body’s system by releasing hormones.

Clinical Quality Mesenchymal Stem Cell Therapy

Mesenchymal stem cells (MSCs) are advantageous over other stem cells types for a variety of reasons. First, they avoid the ethical issues that surround embryonic stem cell research.

Second, repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogeneic transplantation. MSCs reduce both the risks of rejection and complications of transplantation.

Third, there have been advances in the use of umbilical cord mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, and bone fractures, because MSCs can exert regenerative effects through honing to sites of damage, paracrine signaling, regulating the immune response, and affecting the microenvironment.

In combination, these traits make Mesenchymal stem cells of intense therapeutic interest, because they represent a population of cells with the potential to treat a wide range of acute and degenerative diseases.

Mesenchymal Stem Cells have a range of benefits compared to other stem cell types, as presented below:

1. Well-Characterized: Mesenchymal stem cells are a well-characterized population of adult stem cells, with over 36,000 scientific articles published about them.

2. Non-Controversial: Mesenchymal stem cells avoid the ethical issues of embryonic stem cells, as they can be derived from sources that include adult bone marrow and adipose tissue.

4. Ease of Growth in Culture: Advanced knowledge exists for how to grow mesenchymal stem cells in culture, including protocols for isolation, expansion, and differentiation.

5. Flexible Propagation: Mesenchymal stem cells can be grown and propagated in culture for extended periods, without losing differentiation potential.

6. Role as Regulatory Cells: Mesenchymal stem cells synthesize and secrete a variety of macromolecules that are known regulators of hematopoietic and bone-resorbing cells.

7. Favorable Immune Status: Mesenchymal stem cells lack the co-stimulatory molecules of the B7 family that is required to initiate an immune response. This allows the administration of MSC preparations across MHC barriers without concern for immunological rejection or the need for immunosuppression, making Mesenchymal stem cells a universal stem cells source.

Mesenchymal stem cells (MSCs) are advantageous over other stem cells types for a variety of reasons. First, they avoid the ethical issues that surround embryonic stem cell research.

Second, repeated studies have found MSCs to be immuno-privileged, which make them an advantageous cell type for allogeneic transplantation.

Third, there have been advances in the use of umbilical cord mesenchymal stem cells to regenerate human tissues, including cartilage, meniscus, tendons, and bone fractures, because MSCs can exert regenerative effects through homing to sites of damage, paracrine signaling, regulating the immune response, and affecting the microenvironment.

Young Stem Cells and Old Stem Cells:

Umbilical cord tissue represents a unique, easily accessible and noncontroversial source of early stem cells that can be readily processed for therapeutic use.

Our laboratories have compared the properties of Umbilical cord mesenchymal stem cells and from adult sources such as adipose and found some important differences:

The difference between young and old MSCs in morphology, cell surface antigen phenotype, proliferation, gene expression, and immunomodulatory ability are proven. When you expand the numbers of young mesenchymal stem cells into further passages, senescent MSCs display a characteristically enlarged and flattened morphology and different gene expression profiles.

Over a two to three weeks period, Mesenchymal stem cells can rapidly proliferate achieving potentially thousands of fold expanded cells. However, inappropriate expansion reduces the quality of the MSCs. In addition, particular therapeutic properties of the mesenchymal stem cells will be lost during prolonged culture, for example, the cardioprotective effect of mesenchymal stem cells grown to passage 3 is significantly reduced compared to passage 1 mesenchymal stem cells.

In our laboratories as a standard, the most important parameter we use for determining clinical cell culture is using population doubling time. Population doubling time refers to the number of times two-fold increase (doubling) of the cells in culture. Population doubling time directly correlates with replicative senescence, loss of potency and genomic instability. Mesenchymal stem cell senescence is reported in cultures with a population doubling time from 10-40.

Thus, our laboratories maintain just passage 1 culture with a restriction on doubling of 6-10 times. This maintains their naive status and higher activity levels.

Thus, as naïve cells, mesenchymal stem cells extracted from cord tissues have greater therapeutic potential than adult cells. Studies have also shown that cord tissue-derived mesenchymal stem cells appear to have greater in vitro capacity for expansion and shorter doubling times; they can, therefore, generate a larger cell mass in less time than can be achieved with adult stem cells. This property may be related to a greater length of chromosomal telomeres, which have been found to shorten with increased rounds of cell division. This suggests that primitive mesenchymal stem cells have a greater ability to expand in culture than do adult mesenchymal stem cells, perhaps due to their relative youth.